T0	KEYPHRASE-NOTYPES 0 12	Lyme disease
T1	KEYPHRASE-NOTYPES 14 16	LD
T2	KEYPHRASE-NOTYPES 23 43	tick-borne infection
T3	KEYPHRASE-NOTYPES 58 89	spirochete Borrelia burgdorferi
T4	KEYPHRASE-NOTYPES 91 101	Primary LD
T5	KEYPHRASE-NOTYPES 125 141	flu-like ifiness
T6	KEYPHRASE-NOTYPES 145 153	children
T7	KEYPHRASE-NOTYPES 184 199	diagnostic rash
T8	KEYPHRASE-NOTYPES 209 225	erythema migrans
T9	KEYPHRASE-NOTYPES 227 229	EM
T10	KEYPHRASE-NOTYPES 234 249	] Rheumatologic
T11	KEYPHRASE-NOTYPES 263 275	dermatologic
T12	KEYPHRASE-NOTYPES 280 306	cardiologic manifestations
T13	KEYPHRASE-NOTYPES 310 321	systemic LD
T14	KEYPHRASE-NOTYPES 337 354	primary infection
T15	KEYPHRASE-NOTYPES 358 363	weeks
T16	KEYPHRASE-NOTYPES 367 373	months
T17	KEYPHRASE-NOTYPES 394 414	initial presentation
T18	KEYPHRASE-NOTYPES 418 420	LD
T19	KEYPHRASE-NOTYPES 422 436	wide variety
T20	KEYPHRASE-NOTYPES 440 460	neurologic syndromes
T21	KEYPHRASE-NOTYPES 488 496	children
T22	KEYPHRASE-NOTYPES 501 507	adults
T23	KEYPHRASE-NOTYPES 513 515	LD
T24	KEYPHRASE-NOTYPES 530 544	acute myositis
T25	KEYPHRASE-NOTYPES 556 570	encephalopathy
T26	KEYPHRASE-NOTYPES 581 593	facial palsy
T27	KEYPHRASE-NOTYPES 598 616	aseptic meningitis
T28	KEYPHRASE-NOTYPES 648 673	neurologic manifestations
T29	KEYPHRASE-NOTYPES 677 698	] \ nThe nonspecificity
T30	KEYPHRASE-NOTYPES 702 724	clinical presentations
T31	KEYPHRASE-NOTYPES 729 740	limitations
T32	KEYPHRASE-NOTYPES 744 764	laboratory diagnosis
T33	KEYPHRASE-NOTYPES 780 789	diagnosis
T34	KEYPHRASE-NOTYPES 793 809	neuroborreliosis
T35	KEYPHRASE-NOTYPES 817 830	Lyme serology
T36	KEYPHRASE-NOTYPES 865 876	systemic LD
T37	KEYPHRASE-NOTYPES 878 893	false positives
T38	KEYPHRASE-NOTYPES 908 935	asymptomatic seroconversion
T39	KEYPHRASE-NOTYPES 937 947	antibodies
T40	KEYPHRASE-NOTYPES 951 967	oral spirochetes
T41	KEYPHRASE-NOTYPES 969 984	prior infection
T42	KEYPHRASE-NOTYPES 989 1015	immunologic cross reaction
T43	KEYPHRASE-NOTYPES 1019 1034	pathogens
T44	KEYPHRASE-NOTYPES 1036 1051	Several authors
T45	KEYPHRASE-NOTYPES 1072 1082	precedence
T46	KEYPHRASE-NOTYPES 1086 1103	clinical criteria
T47	KEYPHRASE-NOTYPES 1130 1149	treatment decisions
T48	KEYPHRASE-NOTYPES 1153 1161	patients
T49	KEYPHRASE-NOTYPES 1167 1179	suspected LD
T50	KEYPHRASE-NOTYPES 1182 1186	3-5 ]
T51	KEYPHRASE-NOTYPES 1192 1215	new neurologic symptoms
T52	KEYPHRASE-NOTYPES 1226 1233	concert
T53	KEYPHRASE-NOTYPES 1239 1268	clinical manifestations
T54	KEYPHRASE-NOTYPES 1280 1282	LD
T55	KEYPHRASE-NOTYPES 1288 1297	diagnosis
T56	KEYPHRASE-NOTYPES 1301 1317	neuroborreliosis
T57	KEYPHRASE-NOTYPES 1346 1357	individuals
T58	KEYPHRASE-NOTYPES 1363 1377	systemic signs
T59	KEYPHRASE-NOTYPES 1381 1383	LD
T60	KEYPHRASE-NOTYPES 1422 1435	clinical data
T61	KEYPHRASE-NOTYPES 1439 1460	seropositive children
T62	KEYPHRASE-NOTYPES 1491 1518	initial clinical evaluation
T63	KEYPHRASE-NOTYPES 1531 1540	diagnosis
T64	KEYPHRASE-NOTYPES 1544 1560	neuroborreliosis
T65	KEYPHRASE-NOTYPES 1573 1578	range
T66	KEYPHRASE-NOTYPES 1582 1598	neurologic signs
T67	KEYPHRASE-NOTYPES 1602 1610	children
T68	KEYPHRASE-NOTYPES 1616 1638	positive Lyme serology
